SWEDISH ORPHAN/S (OTCMKTS:SWTUY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.
According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “
Separately, ValuEngine raised SWEDISH ORPHAN/S from a “hold” rating to a “buy” rating in a report on Thursday, July 19th.
OTCMKTS SWTUY opened at $23.92 on Friday. The company has a market cap of $7.92 billion, a P/E ratio of 47.84, a price-to-earnings-growth ratio of 3.64 and a beta of 2.14. SWEDISH ORPHAN/S has a one year low of $12.55 and a one year high of $31.96. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.46 and a current ratio of 1.89.
SWEDISH ORPHAN/S Company Profile
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B.
Read More: Earnings Per Share
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SWEDISH ORPHAN/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SWEDISH ORPHAN/S and related companies with MarketBeat.com's FREE daily email newsletter.